Eribulin is an immune potentiator in breast cancer by up-regulating human leukocyte antigen class I expression via the induction of NLRC5
The effect of Eribulin in RNA expression was addressed by RNA-sequence using Eribulin treated MCF7 breast cancer cell line. Overall design: MCF7 cells were treated by Eribulin (10nM) for 2day, then total RNA was isolated and analyzed by RNA-sequence.